Novartis Shares Two Year Beovu Data From Diabetic Macular Edema Studies

Novartis AG NVS has reported data from two Phase 3 trials assessing Beovu (brolucizumab) 6 mg versus Regeneron Pharmaceuticals Inc's REGN Eylea (aflibercept) 2 mg in patients with diabetic macular edema (DME).
Two-year (week 100) data of the KITE study showed consistent results as one year of greater reductions versus aflibercept in central subfield thickness (CSFT), a number of eyes with retinal fluid (a biomarker of the disease), and maintenance of best-corrected visual acuity (BCVA).
Year two findings from KESTREL, another pivotal Phase 3 trial of Beovu in DME, are due to read out in Q4 of 2021.
Another Phase 3 trial, KINGFISHER, met its primary endpoint of non-inferiority to aflibercept in the change in BCVA from baseline at year one (week 52) when dosed every four weeks.
Further details of KITE and KINGFISHER will be presented at upcoming medical meetings.
Related: Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety.
Price Action: NVS shares closed 0.67% higher at $94.46 on Monday.

Overview Rating:

Speculative

0100